Vertex Pharmaceuticals Incorporated (VRTX) Stake Decreased by Candriam Luxembourg S.C.A.
Candriam Luxembourg S.C.A. reduced its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 355,775 shares of the pharmaceutical company’s stock after selling 3,087 shares during the quarter. Vertex Pharmaceuticals comprises 0.9% of Candriam Luxembourg S.C.A.’s investment portfolio, making the stock its 13th largest position. Candriam Luxembourg S.C.A.’s holdings in Vertex Pharmaceuticals were worth $53,316,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of VRTX. Wealthstreet Investment Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $5,256,000. LS Investment Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 24.3% during the fourth quarter. LS Investment Advisors LLC now owns 8,579 shares of the pharmaceutical company’s stock valued at $1,286,000 after purchasing an additional 1,679 shares in the last quarter. Whittier Trust Co. boosted its position in shares of Vertex Pharmaceuticals by 153.5% during the fourth quarter. Whittier Trust Co. now owns 991 shares of the pharmaceutical company’s stock valued at $149,000 after purchasing an additional 600 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in shares of Vertex Pharmaceuticals by 16.1% during the fourth quarter. Oppenheimer & Co. Inc. now owns 5,159 shares of the pharmaceutical company’s stock valued at $773,000 after purchasing an additional 714 shares in the last quarter. Finally, C WorldWide Group Holding A S boosted its position in shares of Vertex Pharmaceuticals by 27.4% during the fourth quarter. C WorldWide Group Holding A S now owns 48,588 shares of the pharmaceutical company’s stock valued at $7,281,000 after purchasing an additional 10,442 shares in the last quarter. Hedge funds and other institutional investors own 92.81% of the company’s stock.
In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 125,000 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $141.35, for a total transaction of $17,668,750.00. Following the completion of the sale, the chief executive officer now owns 237,407 shares of the company’s stock, valued at $33,557,479.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paul M. Silva sold 9,883 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $173.50, for a total value of $1,714,700.50. Following the sale, the senior vice president now directly owns 25,228 shares of the company’s stock, valued at approximately $4,377,058. The disclosure for this sale can be found here. In the last quarter, insiders have sold 403,165 shares of company stock valued at $62,154,183. 1.80% of the stock is owned by company insiders.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.08. The company had revenue of $651.63 million during the quarter, compared to analysts’ expectations of $592.49 million. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. Vertex Pharmaceuticals’s revenue for the quarter was up 42.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.35 earnings per share. equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 1.63 EPS for the current year.
Vertex Pharmaceuticals announced that its board has initiated a stock buyback plan on Wednesday, January 31st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the pharmaceutical company to buy shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.
Several research firms recently weighed in on VRTX. Barclays lifted their price target on Vertex Pharmaceuticals from $180.00 to $200.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. HC Wainwright restated a “hold” rating and set a $103.00 price target on shares of Vertex Pharmaceuticals in a research report on Thursday, February 1st. Zacks Investment Research lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, January 21st. Robert W. Baird restated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. Finally, Citigroup restated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, February 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and twenty-five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $180.07.
COPYRIGHT VIOLATION WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Stake Decreased by Candriam Luxembourg S.C.A.” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-stake-decreased-by-candriam-luxembourg-s-c-a/1860610.html.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.